Background {#Sec1}
==========

Extracorporeal membrane oxygenation (ECMO) is a salvage therapy for patients with severe respiratory and heart failure \[[@CR1]--[@CR4]\]. Patients frequently require large-volume fluid resuscitation during the initial phases of ECMO treatment in order to maintain a sufficient amount of vascular blood drainage for extracorporeal blood flow \[[@CR5]--[@CR7]\]. This need for liberal fluid infusion during ECMO treatment is further exacerbated by the fact that most patients undergoing ECMO treatment are in an intravascular hypovolemic state aggravated by systemic capillary leakage \[[@CR8], [@CR9]\]. In addition to the inevitable large-volume fluid resuscitation, administration of blood products for bleeding events accompanying ECMO implantation and reduced urine volume caused by concomitant acute kidney injury (AKI) also play a part in the aggravation of fluid overload in patients undergoing ECMO \[[@CR10]--[@CR14]\]. Furthermore, excessive positive fluid balance during intensive care unit (ICU) stay is reported to affect outcome, and a positive fluid balance was found to increase the risk of mortality in patients with septic shock \[[@CR15]--[@CR17]\]. In addition, large-volume intravenous fluid therapy was associated with more cardiac arrest events and increased pulmonary edema in patients resuscitated from cardiac arrest events \[[@CR18]\], and excessive volume overload was found to be linked to poor survival, even in patients undergoing ECMO therapy \[[@CR19], [@CR20]\]. Therefore, although large-volume resuscitation is necessary in most patients initiating ECMO, excessive volume overload may lead to poor outcomes. The clinically significant volume overload threshold has not yet been established.

Cumulative fluid balance (CFB) has been widely used as a surrogate marker of fluid therapy during ICU treatment. Higher CFB values after ICU admission were found to increase the risk of AKI development \[[@CR21]\]. In addition, CFB has been reported to be associated with worse clinical outcomes in patients with sepsis \[[@CR15], [@CR22]\], acute lung injury \[[@CR23], [@CR24]\], and cancer \[[@CR25]\]. Therefore, the association between CFB during the initial phase of ECMO treatment and outcome was evaluated, and a clinically significant threshold level of CFB that affects outcome was investigated.

Methods {#Sec2}
=======

Patient selection {#Sec3}
-----------------

Patients who received ECMO at Yonsei University Health System, Seoul National University Hospital, and Seoul National University Bundang Hospital from January 2005 to May 2016 were initially screened (*n* = 1499). Patients who met the following criteria were excluded (*n* = 776): (1) age under 18 years, (2) ECMO support for less than 24 h, (3) death within 3 days from ECMO initiation, (4) switching of ECMO modality, (5) end-stage renal disease with dialysis at admission, (6) transfer after initiating ECMO in other hospitals, and (7) missing data. As a result, 406 patients who underwent ECMO for cardiovascular causes (cardiovascular disease \[CVD\] group) and 317 patients who underwent ECMO for non-cardiovascular causes (non-CVD group) were included in the final analysis (Fig. [1](#Fig1){ref-type="fig"}). Although myocarditis is caused by infection, patients with myocarditis were included in the CVD group on the basis of pathophysiologic considerations. The study protocol was approved by the institutional review boards of Yonsei University Health System and Seoul National University Bundang Hospital. Informed consent was waived by the institutional review boards owing to the retrospective study design.Fig. 1Flowchart of participant enrollment. *ECMO* Extracorporeal membrane oxygenation, *ESRD* End-stage renal disease

Data collection {#Sec4}
---------------

The patients' demographic and laboratory data at the time of ECMO initiation were retrieved from electronic medical records. The data included age, sex, height, weight, underlying medical conditions, cause of ECMO, mode of ECMO (venoarterial \[VA\]-ECMO or venovenous \[VV\]-ECMO), ECMO settings, and total fluid input and output on each day of ECMO therapy. Laboratory data, including white blood cell count, hemoglobin, sodium, potassium, bicarbonate, albumin, bilirubin, C-reactive protein, blood urea nitrogen, creatinine, and arterial blood gas analysis on the day of ECMO implantation, were also collected.

Acute Physiology and Chronic Health Evaluation (APACHE) II scores were calculated on the basis of medical records. The ENCOURAGE (Prediction of cardiogenic shock outcome for AMI patients salvaged by VA-ECMO) and PRESERVE (Predicting death for severe ARDS on VV-ECMO) scores were also calculated for patients in the CVD and non-CVD groups, respectively \[[@CR26], [@CR27]\]. The Modification of Diet in Renal Disease equation was used to determine the estimated glomerular filtration rate (eGFR) \[[@CR28]\]. Baseline serum creatinine was defined as the average serum creatinine within 3 months prior to ICU admission. For those whose baseline creatinine levels were not obtainable, urine output was used for AKI diagnosis. Development of AKI within 72 h of ECMO implantation was evaluated using the Kidney Disease: Improving Global Outcomes (KDIGO) AKI criteria \[[@CR29]\]. The amount of fluid administered was decided by the intensive care specialists. Crystalloid fluids were used to maintain fluid therapy for all patients. The low-chloride fluid resuscitation strategy had not been widely practiced in the institutions during the study period. Cumulative input was defined as total administration of fluid within 3 days of ECMO initiation, which was divided by patients' body weight at the time of ECMO initiation. In addition, cumulative total output was defined as the sum of all fluid drainage from patients, and cumulative urine output as the sum of the total amount of urine during 3 days from ECMO initiation divided by body weight. CFB was defined as cumulative input minus cumulative total output. Daily fluid balance before ECMO was defined as total fluid input minus total output from ICU admission to ECMO initiation, which was divided by ICU length of stay (LOS) and patients' body weight. If patients were admitted to the ICU after surgery, fluid balance during surgery was also included in daily fluid balance before ECMO.

ECMO protocol {#Sec5}
-------------

The decision to initiate ECMO therapy was made by the treating intensive care specialist or the attending cardiothoracic surgeons. Indication for ECMO was classified into two categories. Indications for ECMO in the CVD group were as follows:Postcardiotomy statusAcute cardiogenic shock for coronary arterial diseaseAcute myocarditisBridge to cardiac transplant for decompensated heart failurePost-cardiac arrest status

Indications for ECMO in the non-CVD group were as follows:Acute respiratory distress syndrome (ARDS) of any causeBridge to lung transplantMiscellaneous or unknown origin

Cannulations for all ECMO supports were performed by cardiovascular surgeons with limited cut-down using the Seldinger technique \[[@CR30]\]. Either the CAPIOX EBS (Terumo Co., Ltd., Tokyo, Japan) or the QUADROX PLS (Maquet GmbH, Rastatt, Germany) system was used in all patients. The sweep gas flow was set to maintain a partial pressure of carbon dioxide target of 35--45 mmHg under lung rest ventilation strategy. The target ECMO blood pump speed was 3.0--4.5 L/min. Systemic anticoagulation with unfractionated heparin was titrated to maintain activated clotting times (ACT) between 180 and 220 s and between 160 and 180 s for VA-ECMO and VV-ECMO, respectively. ACT was measured using STA R MAX® hemostasis analyzer (Diagnostica Stago, Inc., Parsippany, NJ, USA). Hemolysis markers, such as free plasma hemoglobin and haptoglobin, were monitored every day. Careful inspections were made by the intensive care specialist to determine the cause of hemolysis when plasma hemoglobin levels were greater than 50 mg/dl. ECMO circuit change was performed when ECMO-related technical problems were suspected as the cause of hemolysis. Red blood cell (RBC) transfusion was performed to maintain hemoglobin target between 10 and 11 g/dl. Antithrombin (AT) replacement was performed when AT activities were less than 70%. Other specific ECMO run protocols are delineated in Additional file [1](#MOESM1){ref-type="media"}: Table S1.

Continuous renal replacement therapy protocol {#Sec6}
---------------------------------------------

In the event of the development of AKI, the decision to start continuous renal replacement therapy (CRRT) was made by the attending nephrologist. Generally, CRRT was applied to patients with AKI who had uncontrolled fluid overload, hyperkalemia, or metabolic acidosis. Continuous venovenous hemodiafiltration was applied using Prisma (Gambro Co., Ltd., Hechingen, Germany), Prismaflex (Gambro Co., Ltd.), or multiFiltrate (Fresenius Medical Care GmbH, Bad Homburg, Germany) machines. Biocompatible AN69 ST membranes were used for Prisma and Prismaflex, and polysulfone membranes were used for multiFiltrate. Bicarbonate-containing replacement fluid was administered by the predilution method. CRRT machines were routinely applied via separate lines from the ECMO circuit. However, when additional venous access was not obtainable, CRRT was performed over the same circuit with ECMO. In these cases, CRRT was applied between ECMO pump and oxygenator to avoid air entrainment.

Clinical outcome {#Sec7}
----------------

The patients were followed until their last visit at our centers or death. The primary endpoint was death from any cause within 90 days after ECMO initiation. Survival data were collected through electronic medical records of the hospital and outpatient clinics.

Statistical analysis {#Sec8}
--------------------

Patients in each group were categorized into quartiles according to the CFB of each group. Continuous variables were expressed as mean ± SD. Comparisons of continuous variables were conducted with one-way analysis of variance, and linear trend was analyzed among groups. The normality of the distribution was analyzed using the Kolmogorov-Smirnov test. Variables not normally distributed were expressed as median and IQR and compared with the Jonckheere-Terpstra test. Categorical variables were expressed as percentages and compared with the chi-square test. Cumulative survival curves were derived using the Kaplan-Meier method, and statistical differences were analyzed using the log-rank test. To evaluate the association between outcomes and clinical parameters, a Cox proportional hazards model was used, and data were expressed as HR with 95% CI. This model included propensity scores. The propensity score was obtained by using a multivariate logistic regression analysis to determine whether the CFB of each patient was higher than the median amount. The covariates for adjustment were selected using a stepwise procedure when the *P* value for each variable was less than 0.2. All variables, except those that were already included in the APACHE II score, were included for propensity score calculation. Those who were lost to follow-up were treated as censored in the survival analysis. Cubic spline curve analysis was conducted as previously described by Canaud et al. \[[@CR31]\]. The Cox model for 90-day mortality was used, and cubic spline curves had four equally distributed knots. The threshold of CFB was defined as the point where the lower limit of the 95% CI was higher than 1.0. Analyses were conducted for the CVD and non-CVD groups. Additional evaluations were also conducted after dividing the non-CVD group into a respiratory group and an others group. The respiratory group was defined as patients who underwent ECMO for lung transplant, ARDS, or other pulmonary diseases. All other patients in the non-CVD group were defined as the others group. Statistical significance was defined as *P* \< 0.05. All analyses were conducted using SPSS version 23.0 software (IBM, Armonk, NY, USA) and R language (version 3.3.1; R Foundation for Statistical Computing, Vienna, Austria).

Results {#Sec9}
=======

Baseline characteristics of patients {#Sec10}
------------------------------------

The baseline characteristics of the patients in the CVD group are presented in Table [1](#Tab1){ref-type="table"}. The mean age was 58.4 ± 17.7 years, and 68.2% were male. The most common cause of ECMO implantation was nonoperative CVD, and 98% of patients underwent VA-ECMO. The median CFB was 64.7 ml/kg, whereas the median daily fluid balance throughout the entire period of ECMO was 26.2 ml/kg/d. The median duration of ECMO treatment was 3 days. The age of the patients tended to increase in patients with higher CFB quartiles. Body weight tended to decrease in higher CFB quartiles, but body mass index (BMI) was comparable among the quartiles. In the non-CVD group, the mean age was 55.7 ± 15.7 years, and 65.3% of patients were male. Among these patients, 201 (63.8%) patients received ECMO treatment for respiratory disease, and VA-ECMO was applied for 23% of the patients. The median CFB was 53.5 ml/kg, and median daily fluid balance during the entire ECMO period was 15.9 ml/kg. Patients' weight and BMI were comparable among the CFB quartiles. However, APACHE II scores tended to increase in patients with higher CFB quartiles (Table [2](#Tab2){ref-type="table"}). In the non-CVD group, there were no significant differences in Charlson comorbidity index (*P* = 0.616), APACHE II score (*P* = 0.302), and CFB (*P* = 0.206) between VA-ECMO- and VV-ECMO-treated patients. Regarding the resuscitation volume differences during the study duration, further analyses were made by categorizing the patients into three groups according vintage: 2005--2008, 2009--2012, and 2013--2016. When the CFB quartiles were compared among the vintage groups, no statistical differences were found (Additional file [2](#MOESM2){ref-type="media"}: Figure S1).Table 1Baseline characteristics of patients with cardiovascular diseaseVariablesCFB quartilesTotal*P* for trendQuartile 1Quartile 2Quartile 3Quartile 4Number of patients101102102101406Age (yr)55.0 ± 17.056.5 ± 18.058.9 ± 19.363.1 ± 15.558.4 ± 17.70.001Sex (male, %)74 (73.3)73 (71.6)71 (69.6)59 (58.4)277 (68.2)0.025DM (n, %)38 (37.6)36 (35.3)30 (29.4)30 (29.7)134 (33.0)0.156Hypertension (n, %)48 (47.5)41 (40.2)35 (34.3)45 (44.6)169 (41.6)0.499Malignancy (n, %)6 (5.9)13 (12.7)9 (8.8)7 (6.9)35 (8.6)0.937Charlson comorbidity index2.1 ± 2.12.2 ± 2.01.8 ± 1.71.1 ± 1.51.8 ± 1.9\< 0.001Weight (kg)67.6 ± 11.266.0 ± 12.963.9 ± 12.161.4 ± 10.964.7 ± 12.0\< 0.001Body mass index (kg/m^2^)24.2 ± 3.323.7 ± 3.823.4 ± 3.623.4 ± 3.323.7 ± 3.50.085Body surface area (m^2^)1.7 ± 0.21.7 ± 0.21.7 ± 0.21.6 ± 0.11.7 ± 0.2\< 0.001CFB (ml/kg)\*− 4.8 (− 25.2--9.6)38.2 (27.6--51.4)109.7 (77.4--137.3)222.9 (194.6--272.7)64.7 (20.1--161.7)\< 0.001Daily fluid balance (ml/kg/d)\*^,†^2.3 (− 5.0 to 8.9)13.1 (6.6--27.7)37.8 (23.8--67.0)108.4 (63.4--180.6)26.2 (6.7--68.6)\< 0.001Cumulative input (ml/kg)\*^,¶^165.2 (124.7--216.7)191.6 (168.3--241.8)248.6 (213.4--280.2)371.3 (293.3--482.3)214.5 (157.6--267.2)\< 0.001Cumulative total output (ml/kg)\*^,¶^182.0 (138.2--229.7)149.7 (112.7--201.4)138.6 (113.6--182.0)136.8 (91.1--226.3)153.1 (115.6--201.4)\< 0.001Cumulative urine output (ml/kg)\*^,¶^136.0 (68.5--182.5)100.5 (37.1--143.9)59.8 (21.7--119.8)27.1 (10.0--66.6)95.8 (31.1--150.6)\< 0.001ICU LOS before ECMO (days)\*1 (0--1)1 (0--1)0 (0--1)0 (0--1)1 (0--1)\< 0.001Daily fluid balance before ECMO (ml/kg/d)\*^,‡^1.4 (− 22.4--19.9)11.6 (− 15.7--24.4)11.9 (− 0.6--37.9)− 0.7 (− 6.2--7.4)3.1 (− 8.3--21.6)0.834ECMO cause (n, %) Heart transplant5 (5.0)9 (8.8)2 (2.0)0 (0.0)16 (3.9)0.357 Other cardiotomy22 (21.8)23 (22.5)20 (19.6)21 (20.8)86 (21.2) Nonoperative CVD74 (73.3)70 (68.6)80 (78.4)80 (79.2)304 (74.9)ECMO VA mode (n, %)100 (99.0)98 (96.1)99 (97.1)101 (100.0)398 (98.0)0.530ECMO settings Blood flow rate (L/min)2.8 ± 0.83.0 ± 0.83.0 ± 1.03.1 ± 1.02.9 ± 0.90.006 Blood flow rate (L/min/m^2^)1.6 ± 0.51.8 ± 0.41.8 ± 0.61.9 ± 0.61.8 ± 0.5\< 0.001 FsO~2~ (%)89.4 ± 13.887.9 ± 15.185.3 ± 15.881.3 ± 17.185.9 ± 15.7\< 0.001 ECMO DO~2~I (ml/min/m^2^)272.4 ± 86.7304.4 ± 101.6311.9 ± 134.6344.8 ± 134.9309.3 ± 119.2\< 0.001ECMO duration (days)\*4 (2--6)3 (2--7)4 (2--7)3 (2--6)3 (2--6)0.231Mechanical ventilation (n, %)90 (89.2)100 (98.5)97 (95.3)100 (98.9)387 (95.3)0.015Days of ventilator before ECMO (days)\*1 (0--1)1 (0--1)1 (0--1)0 (0--1)1 (0--1)0.155WBC (× 10^3^/μl)12.8 ± 6.013.8 ± 6.914.6 ± 8.513.6 ± 6.813.7 ± 7.10.293Hemoglobin (g/dl)11.1 ± 2.411.4 ± 2.411.0 ± 2.310.3 ± 2.411.0 ± 2.40.008SaO~2~ (%)\*98.2 (93.3--99.3)97.7 (95.4--98.9)99.3 (97.3--99.8)99.6 (96.8--99.9)98.8 (96.2--99.8)0.001BUN (mg/dl)27.3 ± 16.027.1 ± 15.226.5 ± 11.023.6 ± 12.926.1 ± 14.00.054Creatinine (mg/dl)1.5 ± 0.91.5 ± 0.81.5 ± 0.51.4 ± 0.51.5 ± 0.70.105eGFR (ml/min/1.73 m^2^)60.7 ± 29.558.2 ± 26.854.6 ± 22.958.2 ± 25.857.9 ± 26.40.348Albumin (g/dl)3.0 ± 0.52.9 ± 0.62.7 ± 0.72.6 ± 0.82.8 ± 0.7\< 0.001Bilirubin (mg/dl)1.8 ± 1.72.4 ± 2.61.8 ± 1.91.2 ± 1.21.8 ± 1.90.007CRP (mg/dl)\*32.7 (12.8--82.6)25.6 (6.4--62.6)17.9 (4.1--61.9)9.7 (3.0--47.0)22.7 (3.6--62.3)0.001APACHE II score23.1 ± 9.723.9 ± 8.323.7 ± 10.424.7 ± 9.723.8 ± 9.60.274*Abbreviations: APACHE II* Acute Physiology and Chronic Health Evaluation II, *ARDS* Acute respiratory distress syndrome, *BUN* Blood urea nitrogen, *CFB* Cumulative fluid balance for 3 days from extracorporeal membrane oxygenation initiation, *CRP* C-reactive protein, *CVD* Cardiovascular disease, *DM* Diabetes mellitus, *ECMO* Extracorporeal membrane oxygenation, *eGFR* Estimated glomerular filtration rate, *FsO*~*2*~ Fraction of sweep gas inlet oxygen supplied to extracorporeal membrane oxygenation, *SaO*~*2*~ Oxygen saturation, *VA* Venoarterial access, *WBC* White blood cell\*Data are expressed as median and IQR and compared by Jonckheere-Terpstra test^†^Fluid balance during entire ECMO treatment^¶^During 3 days from ECMO commencement^‡^Daily fluid balance during ICU admission before ECMO commencementTable 2Baseline characteristics of patients with non-cardiovascular diseaseVariablesCFB quartilesTotal*P* for trendQuartile 1Quartile 2Quartile 3Quartile 4Number of patients79798079317Age (yr)53.2 ± 16.256.1 ± 14.957.2 ± 15.056.3 ± 16.855.7 ± 15.70.192Sex (male, %)55 (69.6)53 (67.1)52 (65.0)47 (59.5)207 (65.3)0.176DM (n, %)19 (24.1)17 (21.5)15 (18.8)16 (20.3)67 (21.1)0.490Hypertension (n, %)21 (26.6)13 (16.5)14 (17.5)21 (26.6)69 (21.8)0.962Malignancy (n, %)25 (31.6)22 (27.8)22 (27.5)24 (30.4)93 (29.3)0.856Charlson comorbidity index2.1 ± 2.21.9 ± 2.01.6 ± 1.71.6 ± .2.01.8 ± 2.00.076Weight (kg)63.8 ± 15.863.1 ± 12.864.1 ± 16.161.0 ± 12.263.0 ± 14.30.300Body mass index (kg/m^2^)22.9 ± 4.423.4 ± 4.523.6 ± 5.122.7 ± 3.923.2 ± 4.50.900Body surface area (m^2^)1.7 ± 0.21.7 ± 0.21.6 ± 0.21.6 ± 0.21.7 ± 0.20.151CFB (ml/kg)*\**− 3.9 (− 19.8--6.8)34.5 (25.6--42.7)72.5 (60.2--87.5)194.7 (147.8--265.5)53.5 (16.9--106.7)\< 0.001Daily fluid balance (ml/kg/d)\*^,†^4.3 (− 2.7--12.9)12.8 (7.1--19.7)21.1 (11.2--35.9)54.0 (29.5--101.8)15.9 (7.1--36.4)\< 0.001Cumulative input (ml/kg)\*^,¶^195.5 (165.3--264.7)206.4 (166.2--263.6)246.2 (192.4--292.3)338.6 (271.8--422.5)231.8 (180.8--298.8)\< 0.001Cumulative total output (ml/kg) \*^,¶^206.6 (163.9--274.9)166.2 (132.2--221.7)173.7 (126.7--217.0)127.7 (92.0--212.9)183.2 (130.4--233.9)\< 0.001Cumulative urine output (ml/kg) \*^,¶^107.2 (8.1--180.9)98.3 (13.2--163.5)75.7 (15.6--127.8)42.7 (17.3--109.8)83.9 (14.0--159.6)0.055ICU LOS before ECMO (days)\*2.5 (0--6)2 (1--4)1 (0--5)1 (0--5)2 (0--5)0.636Daily fluid balance before ECMO (ml/kg/d)\*^,‡^6.8 (− 4.8--18.2)17.0 (7.6--35.6)12.7 (4.0--45.1)22.0 (4.0--49.8)12.2 (3.9--32.5)\< 0.001ECMO cause (n, %) Lung transplant17 (21.5)14 (17.9)12 (15.2)5 (6.3)48 (15.2)0.081 ARDS17 (21.5)19 (24.4)14 (17.7)25 (31.6)75 (23.8) Other pulmonary13 (16.5)21 (26.9)17 (21.5)27 (34.2)78 (24.8) Others32 (40.5)25 (31.6)37 (46.3)22 (27.8)116 (36.6)ECMO VA mode (n, %)18 (22.7)12 (15.2)22 (27.5)21 (26.6)73 (23.0)0.321ECMO settings Blood flow rate (L/min)3.1 ± 0.83.0 ± 0.73.1 ± 0.83.1 ± 0.83.1 ± 0.80.661 Blood flow rate (L/min/m^2^)1.8 ± 0.51.8 ± 0.41.8 ± 0.51.8 ± 0.51.8 ± 0.50.965 FsO~2~ (%)91.1 ± 13.792.0 ± 13.790.7 ± 13.685.0 ± 16.689.7 ± 14.60.008 ECMO DO~2~I (ml/min/m^2^)297.3 ± 87.9302.6 ± 93.8281.2 ± 89.5306.0 ± 115.2297.0 ± 97.60.889ECMO duration (days)*\**8 (4--16)8 (3--14)8 (3--12)6 (3--12)8 (3--13)0.119Mechanical ventilation (n, %)77 (97.5)77 (97.5)78 (97.5)78 (98.7)310 (97.8)0.785Days of ventilator before ECMO (days)\*3 (1--4)2 (2--3)2 (0--3)3 (1--5)3 (1--3)0.377WBC (×10^3^/μl)11.6 ± 6.612.8 ± 7.212.1 ± 7.914.0 ± 8.712.6 ± 7.60.108Hemoglobin (g/dl)10.8 ± 2.011.1 ± 2.510.4 ± 1.910.3 ± 2.510.7 ± 2.20.042SaO~2~ (%)\*94.0 (88.2--98.8)94.4 (90.1--98.0)93.2 (80.7--98.5)95.3 (89.3--99.0)94.4 (88.0--98.7)0.707BUN (mg/dl)31.2 ± 20.626.3 ± 16.927.2 ± 14.829.5 ± 25.428.5 ± 19.90.684Creatinine (mg/dl)1.4 ± 1.01.2 ± 0.81.3 ± 0.91.1 ± 0.91.3 ± 0.90.305eGFR (ml/min/1.73 m^2^)89.9 ± 62.794.3 ± 61.077.7 ± 54.890.6 ± 51.488.1 ± 57.70.622Albumin (g/dl)2.7 ± 0.62.8 ± 0.62.6 ± 0.72.5 ± 0.72.7 ± 0.60.026Bilirubin (mg/dl)2.9 ± 3.73.4 ± 5.43.0 ± 3.81.9 ± 2.02.8 ± 3.90.108CRP (mg/dl) *\**69.7 (28.1--155.2)74.7 (32.2--141.6)85.0 (17.9--199.1)99.2 (22.0--170.8)81.2 (23.7--176.8)0.735APACHE II score18.9 ± 7.320.0 ± 7.319.6 ± 7.724.1 ± 8.720.7 ± 8.0\< 0.001*Abbreviations: APACHE II* Acute Physiology and Chronic Health Evaluation II, *ARDS* Acute respiratory distress syndrome, *BUN* Blood urea nitrogen, *CFB* Cumulative fluid balance for 3 days from extracorporeal membrane oxygenation initiation, *CRP* C-reactive protein, *CVD* Cardiovascular disease, *DM* Diabetes mellitus, *ECMO* Extracorporeal membrane oxygenation, *eGFR* Estimated glomerular filtration rate, *FsO*~*2*~ Fraction of sweep gas inlet oxygen supplied to extracorporeal membrane oxygenation, *SaO*~*2*~ Oxygen saturation, *VA* Venoarterial access, *WBC* White blood cell\*Data are expressed as median and IQR and compared by Jonckheere-Terpstra test^†^Fluid balance during entire ECMO treatment^¶^During 3 days from ECMO commencement^‡^Daily fluid balance during ICU admission before ECMO commencement

Outcome of patients {#Sec11}
-------------------

In the CVD group, AKI occurred in 306 (75.4%) patients and CRRT was commenced in 127 (31.3%) patients during the initial 3 days of ECMO initiation. The occurrence rate of AKI tended to increase in quartiles with higher CFB values. In addition, in the CVD group, median ICU LOS was 8 days. A total of 207 deaths (51.0%) occurred within 90 days of ECMO initiation, and the mortality rate tended to increase in higher CFB quartiles (*P* \< 0.001). In the non-CVD group, 184 (70.0%) patients underwent AKI, and CRRT was applied in 92 (29.0%) patients during first 3 days of ECMO commencement. Both AKI occurrence (*P* = 0.011) and CRRT application rates (*P* = 0.011) tended to increase in patients with higher CFB. Patients treated with VA-ECMO had a significantly higher incidence of AKI than those treated with VV-ECMO (*P* = 0.014). The median ICU LOS was 16 days. During the 90 days of ECMO initiation, a total of 209 (65.9%) deaths occurred (Table [3](#Tab3){ref-type="table"}).Table 3Outcome of patients according to cumulative fluid balance quartilesVariablesCFB quartilesTotal*P* for trendQuartile 1Quartile 2Quartile 3Quartile 4Cardiovascular disease Incident AKI (n, %)60 (59.3)76 (74.4)86 (84.3)84 (83.1)306 (75.4)\< 0.001 CRRT treatment (n, %)*\**26 (25.7)24 (23.5)48 (47.1)29 (28.7)127 (31.3)0.114 Days of CRRT before ECMO (days)^†^0 (0--1)0 (0--1)1 (0--1)0 (0--2)1 (0--1)0.082 ICU LOS (days)^†,‡^10 (5--16)10 (6--18)7 (3--14)7 (4--14)8 (4--15)0.014 90-day mortality (n, %)35 (34.7)43 (42.2)71 (69.6)58 (57.4)207 (51.0)\< 0.001Non-cardiovascular disease Incident AKI (n, %)47 (68.1)34 (53.1)54 (76.1)49 (83.1)184 (70.0)0.011 CRRT treatment (n, %)\*17 (21.5)16 (20.3)32 (40.0)27 (34.2)92 (29.0)0.011 Days of CRRT before ECMO (days)^†^1 (0--2)1 (1--2)2 (1--2)1 (1--2)3 (1--3)0.483 ICU LOS (days)^†,‡^18 (10--33)17 (11--28)13 (8--31)17 (6--40)16 (9--32)0.239 90-day mortality (n, %)49 (62.0)43 (54.4)63 (78.8)54 (68.4)209 (65.9)0.069*Abbreviations: AKI* Acute kidney injury, *CFB* Cumulative fluid balance, *CRRT* Continuous renal replacement therapy, *ECMO* Extracorporeal membrane oxygenation, *ICU* Intensive care unit, *LOS* Length of stay\*Continuous renal replacement therapy imitation during the first 3 days of ECMO commencement^†^Data are expressed as median and IQR and compared by Jonckheere-Terpstra test^‡^LOS was presented in patients who survived at 30th day from ECMO initiation

Relationship between CFB quartile groups and mortality {#Sec12}
------------------------------------------------------

The Kaplan-Meier curves revealed that the cumulative survival rates of CFB quartiles 3 (*P* \< 0.001) and 4 (*P* \< 0.001) were significantly lower than those of CFB quartiles 1 and 2 in the CVD group (Fig. [2a](#Fig2){ref-type="fig"}). The non-CVD group was further divided into those initiating ECMO for respiratory failure (respiratory group) and other causes (others group). The characteristics of the respiratory group are presented in Additional file [1](#MOESM1){ref-type="media"}: Table S2. In patients in the respiratory group, the cumulative survival rate of CFB quartile 4 was significantly lower than quartile 1 (*P* = 0.047) (Fig. [2b](#Fig2){ref-type="fig"}). In addition, in the others group, CFB quartile 4 showed a significantly lower cumulative survival rate than quartile 1 (*P* = 0.004) and quartile 2 (*P* = 0.001) (Fig. [2c](#Fig2){ref-type="fig"}). When patients in the non-CVD group were divided into those treated with VA-ECMO or VV-ECMO, those treated with VA-ECMO had significantly lower cumulative survival rates than those treated with VV-ECMO (*P* = 0.002).Fig. 2Kaplan-Meier (KM) plots for 90-day mortality in each cumulative fluid balance quartile. **a** KM plots representing patients with cardiovascular disease. **b** KM plots representing patients with respiratory disease. **c** KM plots representing patients with other disease. \*Median and IQR of cumulative fluid balance (ml/kg) for each quartile

In addition, when the association between CFB and mortality was further evaluated using multivariate Cox proportional hazards regression analyses, in the CVD group, the risk of mortality significantly increased in patients in CFB quartiles 3 (HR, 2.58; 95% CI, 1.62--4.11; *P* \< 0.001) and 4 (HR, 2.11; 95% CI, 1.26--3.54; P = 0.004) compared with that of patients in CFB quartile 1. However, the mortality risk did not show a significant increase among patients in CFB quartile 2. Similarly, in the non-CVD group, the mortality risk of CFB quartiles 3 (HR, 1.66; 95% CI, 1.06--2.59; *P* = 0.026) and 4 (HR, 1.69, 95% CI, 1.05--2.72; *P* = 0.03) was significantly higher than quartile 1, whereas mortality risk did not significantly differ between CFB quartiles 1 and 2 (Table [4](#Tab4){ref-type="table"}). These findings imply that a CFB below the level of CFB quartile 3 in both the CVD and non-CVD groups may not increase the risk of mortality. When CFB was considered as a continuous variable, log-transformed CFB was independently associated with 90-day mortality in both the CVD group (HR, 1.76; 95% CI, 1.37--2.27; *P* \< 0.001) and the non-CVD group (HR, 1.46; 95% CI, 1.17--1.83; *P* \< 0.001) (Table [5](#Tab5){ref-type="table"}).Table 4Cox regression analyses for 90-day mortalityCFB quartilesCardiovascular diseaseNon-cardiovascular diseaseUnadjustedAdjusted\*UnadjustedAdjusted\*HR (95% CI)*P* valueHR (95% CI)*P* valueHR (95% CI)*P* valueHR (95% CI)*P* valueQuartile 11.00 (reference)1.00 (reference)1.00 (reference)1.00 (reference)Quartile 21.17 (0.75--1.83)0.4961.27 (0.77--2.10)0.3420.84 (0.56--1.27)0.4070.79 (0.48--1.30)0.345Quartile 32.82 (1.88--4.23)\< 0.0012.58 (1.62--4.11)\< 0.0011.61 (1.11--2.34)0.0121.66 (1.06--2.59)0.026Quartile 42.24 (1.47--3.41)\< 0.0012.11 (1.26--3.54)0.0041.37 (0.93--2.02)0.1081.69 (1.05--2.72)0.030*CFB* Cumulative fluid balance\*Adjusted for age, sex, Charlson comorbidity index, Acute Physiology and Chronic Health Evaluation II score, and propensity scorePropensity score was obtained by logistic regression analysis with covariables body mass index, extracorporeal membrane oxygenation (ECMO) pump time, ECMO blood flow rate, albumin, total carbon dioxide, acute kidney injury stageThe 27 (3.7%) patients who were lost to follow-up were treated as censoredTable 5Cox regression analyses for 90-day mortality with cumulative fluid balance, cumulative input, and outputModelsVariablesCardiovascular diseaseNon-cardiovascular diseaseHR (95% CI)*P* valueHR (95% CI)*P* valueModel 1CFB\*1.76 (1.37--2.27)\< 0.0011.46 (1.17--1.83)\< 0.001Model 2CFB\*1.67 (1.19--2.34)0.0031.55 (1.16--2.09)0.003Model 3Cumulative input\*^,†^3.35 (1.64--6.83)0.0015.53 (2.60--11.75)\< 0.001Cumulative total output\*^,†^0.56 (0.47--0.76)\< 0.0010.25 (0.14--0.45)\< 0.001Model 4Cumulative input\*^,†^2.66 (1.30--5.44)0.0071.92 (1.08--3.42)0.027Cumulative urine output\*^,†^0.78 (0.67--0.91)0.0010.84 (0.75--0.93)0.001*CFB* Cumulative fluid balanceModel 1: Additionally adjusted for age, sex, Charlson comorbidity index, Acute Physiology and Chronic Health Evaluation II score, and propensity scoreModel 2: Model 1 + daily fluid balance before ECMO\*^,¶^Model 3: Model 2 + cumulative input + cumulative total output without CFBModel 4: Model 2 + cumulative input + cumulative urine output without CFB\*Data were log-transformed^†^During 3 days from extracorporeal membrane oxygenation (ECMO) commencement^¶^Daily fluid balance during intensive care unit admission before ECMO commencementPropensity score was obtained by logistic regression analysis with covariables body mass index, ECMO pump time, ECMO blood flow rate, albumin, total carbon dioxide, acute kidney injury stageThe 27 (3.7%) patients who were lost to follow-up were treated as censored

No significant interactions between APACHE II scores and CFBs were found in both the CVD and non-CVD groups (*P* = 0.521 for CVD group, *P* = 0.166 for non-CVD group). When further adjustments were made for daily fluid balance before ECMO commencement, the relationship between CFB and risk of mortality was preserved in both groups. In addition, cumulative input was independently associated with 90-day mortality even after adjustments were made for cumulative total output and urine output (Table [5](#Tab5){ref-type="table"}).

When multivariate Cox models were analyzed with adjustment for ENCOURAGE score instead of APACHE II score in the CVD group, the relationship between CFB and 90-day mortality remained significant. This relationship was also maintained when adjustments were made for PRESERVE score instead of APACHE II score in patients who had undergone VV-ECMO in the non-CVD group (Additional file [1](#MOESM1){ref-type="media"}: Table S3).

Significant CFB threshold level in ECMO patients {#Sec13}
------------------------------------------------

To further investigate the CFB threshold level that considerably increases the risk of mortality in ECMO patients, the relationship between CFB and mortality risk was evaluated by cubic spline analyses. In the CVD group, the relative HR of mortality started to increase significantly when CFB values were greater than 82.3 ml/kg (Fig. [3a](#Fig3){ref-type="fig"}). The relative HR increased significantly above CFB levels of 189.6 ml/kg in the respiratory group (Fig. [3b](#Fig3){ref-type="fig"}). In the others group, relative HR tended to increase with higher CFB amounts without statistical significance (Fig. [3c](#Fig3){ref-type="fig"}).Fig. 3Cubic spline curves for the association between cumulative fluid balance and 90-day mortality. **a** Cubic spline curve representing patients with cardiovascular disease. **b** Cubic spline curve representing patients with respiratory disease. **c** Cubic spline curve representing patients with other disease. *Dashed line* = median cumulative fluid balance, *dark gray area* = IQR, *blue line* = permissive threshold of cumulative fluid balance

Discussion {#Sec14}
==========

Large amounts of fluid resuscitation are inevitable in patients initiating ECMO. However, excessive fluid overload can negatively impact outcomes in these patients. In this study, we have shown that CFB was a significant factor affecting mortality risk in patients treated with ECMO. This increase in mortality risk was significant only when the CFB was greater than 82.3 ml/kg in patients who were treated with ECMO for cardiovascular reasons. For those who were treated with ECMO for respiratory causes, mortality risk increase was substantial when CFB was above 189.6 ml/kg.

In patients undergoing ECMO treatment, large-volume fluid administration is frequently required. This is due mainly to disease severity. However, maintaining adequate blood flow for ECMO treatment also plays a part. Patients typically go through a systemic inflammatory response within the first few days of ECMO treatment \[[@CR6]\]. This response induces pathologic vasodilation and fluid loss to the interstitial compartment, resulting in reduced vascular volume. In addition, major conditions associated with patients undergoing ECMO, such as shock and low cardiac output as well as increased capillary leakage related to sepsis-like syndrome, are factors that contribute \[[@CR8], [@CR32], [@CR33]\]. This insufficient intravascular volume can lead to extracorporeal flow failure, which results in more frequent ECMO circuit changes and decreased total ECMO delivery time \[[@CR6], [@CR34]\]. In a retrospective study of pediatric patients who received ECMO treatment for severe pneumonia, frequent circuit change was a significant risk factor for death \[[@CR35]\]. In addition, in a recent investigation of 172 adult patients receiving ECMO, ECMO circuit change was more frequent in patients undergoing concomitant CRRT and ECMO treatment, which resulted in an increased mortality rate in these patients \[[@CR19]\]. Therefore, the administration of sufficient amounts of intravenous fluid to maintain a satisfactory extracorporeal blood flow is a critical component in the management of patients initiating ECMO. Accordingly, in this study, 85.9% of the patients maintained a positive CFB. In addition, the overall average CFB was greater than that of previously reported ICU patients not undergoing ECMO treatment \[[@CR15], [@CR21]\].

Excessive CFB during the initial phase of ECMO was found to be independently associated with increased mortality risk. This association between positive fluid balance and survival in ECMO-treated patients has been proposed previously. In a study of 172 patients receiving VA-ECMO or VV-ECMO treatment, positive fluid balance at the third day of ECMO treatment was an independent predictor of mortality \[[@CR19]\]. In addition, in pediatric patients requiring concomitant ECMO and CRRT treatment, the degree of fluid overload at the time of ECMO initiation was significantly associated with mortality \[[@CR36]\]. In this study, the CFB showed a significant independent relationship with 90-day mortality. However, interestingly, the risk of mortality did not show a significant increase at CFB levels less than 82.3 ml/kg and 189.6 ml/kg for the CVD and respiratory groups, respectively. This finding suggests that patients undergoing ECMO might be able to tolerate fluid replacement below these thresholds. The risk of mortality was elevated in proportion to increases in the CFB above these thresholds, thereby confirming the relationship between CFB and mortality risk suggested in previous investigations \[[@CR19], [@CR20]\]. However, the relationships between mortality and CFB were not linear. As mentioned above, decreased intravascular volume associated with inadequate fluid resuscitation could cause frequent ECMO circuit change, consequently affecting outcome \[[@CR6], [@CR34]\]. This may be one of the reasons why mortality risk did not show a linear relationship at lower CFB levels. In the CVD group, HR of mortality did not seem to increase linearly when CFB was greater than 150 ml/kg. However, the range of the CIs was too wide to infer a significant relationship. This could be due to the fact that the number of patients with extremely high CFB was relatively small. The threshold CFB amounts proposed in this study require further validation. However, in light of the fact that a positive fluid balance during the initial phase of ECMO treatment is generally unavoidable, the CFB thresholds suggested herein, as determined by mortality risk, could serve as a basis for the definition of the clinically significant fluid overload threshold in ECMO-treated patients.

The increased CFB in this study could have been a result of disease severity, considering that those with severe systemic vascular leakage and decreased cardiac function would need larger amounts of fluid resuscitation. The APACHE II scores were not significantly different between CFB quartiles in the CVD group. However, an APACHE II score increase was noticed in the highest quartile of the non-CVD group. Fluid overload may be a result of severe patient conditions, but it could also affect outcome by aggravating vascular wall stretching and worsening vascular permeability \[[@CR37]\]. Because fluid balance and patient severity are interconnected during the treatment course of critically ill patients, it is not easy to delineate a causal relationship \[[@CR37]\]. Accordingly, in the current study, owing to the retrospective nature of the investigation, defining the exact causality between severity and fluid balance was not possible. However, even after adjustments were made for disease severity, a significant increased risk of mortality was noted in the higher CFB quartiles, suggesting that fluid balance could have played an independent role in affecting outcome. Additionally, the fact that no significant interactions were found between disease severity and fluid balance further suggests the possibility that the results presented in this study were an effect of fluid balance rather than disease severity. Nevertheless, further investigations controlling the resuscitation volume amount would be needed to further confirm the findings of this study.

Both decreased output and increased input played a role in increasing CFB in ECMO-treated patients in this study. Lower cumulative total output and cumulative urine output were both independently associated with increased risk of mortality. Meanwhile, higher cumulative input also had a significant relationship with mortality. Notably, this significant relationship with cumulative input was robust even after adjustments were made for cumulative total output or cumulative urine output. Therefore, although decreased output contributes to the positive CFB, increased fluid input still plays a significant role in affecting outcome. Moreover, cumulative input clearly increases the risk of mortality, regardless of output amount, suggesting that the positive input may affect outcome independently of disease severity.

The CFB threshold levels found in this study were higher in the non-CVD group than in the CVD group. The fact that the patients in the non-CVD group were younger and had lower APACHE II scores than those in the CVD group opens the possibility that the non-CVD group could have been healthier and thereby able to tolerate larger amounts of CFB than the CVD group. Hemodynamic status in VV-ECMO-receiving patients is determined by a complex interaction of factors, such as intrathoracic pressure, native cardiac function, pulmonary vascular resistance, systemic vascular tone, and recirculation on VV-ECMO, in addition to intravascular volume. However, the effects of intrathoracic pressure, native cardiac function, and pulmonary vascular resistance on maintaining hemodynamic status are not substantial in patients undergoing VA-ECMO, making these patients relatively more vulnerable to volume than VV-ECMO patients. Furthermore, in VA-ECMO patients, unloading the heart with strict volume control may result in effective preload reduction. However, in VV-ECMO patients, an adequate amount of preload would be needed to maintain cardiac output. This could be one of the reasons that the permissive CFB amount was lower in the CVD group, in which most of the patients underwent VA-ECMO, than in the non-CVD group. Considering that most of the patients in the CVD group underwent VA-ECMO, ECMO modality could also have played a role in determining CFB threshold levels.

There are several limitations of this study. First, although adjustments were made for various confounding factors, including those that reflected the disease severity of the patients and the propensity scores, the limitations owing to the retrospective design should still be recognized. Second, data regarding medications such as diuretics, and hemodynamic parameters including pulmonary arterial pressure, cardiac chamber size, and cardiac output were not obtainable. Third, parameters to ensure sufficient ECMO treatment, such as oxygen consumption, RBC transfusion, amount of recirculation, incidence of catheter change, or ECMO circuit change could not be retrieved from the electronic medical records. Fourth, although protocol-based treatments were applied for all patients within each center, protocol details and bedside care would have varied somewhat from center to center and also over time. Finally, because the indications and modes of ECMO treatment varied, the results of this study may not be generalizable to all patients undergoing ECMO. Although the results were controlled for different indications and ECMO modalities, validation in specific subgroups is needed.

Conclusions {#Sec15}
===========

Excessive CFB during the early phase of ECMO treatment increased the risk of mortality. However, this risk did not increase significantly until the CFB reached specific threshold ranges, which differed according to the disease origin responsible for ECMO commencement. These results suggest that fluid therapy in ECMO-treated patients should be adjusted so as not to exceed this clinically significant fluid overload level. Further interventional studies are needed to confirm these findings.

Additional files
================

 {#Sec16}

Additional file 1:**Table S1.** ECMO protocols for patients. **Table S2.** Baseline characteristics of patients with respiratory disease in non-CVD group. **Table S3.** Cox regression analyses for 90-day mortality with ENCOURAGE and PRESERVE scores. (DOCX 31 kb) Additional file 2:**Figure S1.** Cumulative fluid balance according to ECMO treatment vintage. (PDF 31 kb)

ACT

:   Activated clotting time

AKI

:   Acute kidney injury

APACHE

:   Acute Physiology and Chronic Health Evaluation

ARDS

:   Acute respiratory distress syndrome

AT

:   Antithrombin

BMI

:   Body mass index

CFB

:   Cumulative fluid balance

CRRT

:   Continuous renal replacement therapy

CVD

:   Cardiovascular disease

ECMO

:   Extracorporeal membrane oxygenation

eGFR

:   Estimated glomerular filtration rate

ENCOURAGE

:   Prediction of cardiogenic shock outcome for AMI patients salvaged

ESRD

:   End-stage renal disease

ICU

:   Intensive care unit

LOS

:   Length of stay

PRESERVE

:   Predicting death for Severe ARDS on VV-ECMO

RBC

:   Red blood cell

VA

:   Venoarterial

VV

:   Venovenous

This work was supported by the Soonchunhyang University Research Fund and a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number HI17C1827).

Availability of data and materials {#FPar1}
==================================

The data that support the findings of this study are available from the corresponding author upon reasonable request.

HK, JHS, HL, SHH, THY, SWK, SK, and JTP made substantial contributions to the conception and design of this study. HK, JHP, SP, JHJ, HRY, and YKK made contributions to acquisition and interpretation of data. HK, JTP, and SK drafted the manuscript and revised it for important intellectual content. All authors read and provided final approval of the version to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate {#FPar2}
==========================================

The study protocol was approved by the institutional review boards of Yonsei University Health System and Seoul National University Bundang Hospital. Informed consent was waived by the institutional review boards, owing to the retrospective study design.

Consent for publication {#FPar3}
=======================

Not applicable.

Competing interests {#FPar4}
===================

The authors declare that they have no competing interests.

Publisher's Note {#FPar5}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
